Online inquiry

IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6107MR)

This product GTTS-WQ6107MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Anemia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6107MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11185MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ4555MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ14295MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ936MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ6118MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ8919MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ5987MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ2946MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ANB-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW